Objective. To determine health-state utility (HSU) values for type 2 diabetes (T2D) patients with various clinical conditions in China, and to examine how these conditions are correlated with HSU values. Methods. A consecutive sample of T2D patients was recruited from a tertiary hospital in Suzhou, China. HSU values of T2D patients were measured using the EQ-5D-5L, a new version of the EQ-5D. T2D patients’ clinical data were collected from the survey and the clinical examination; sociodemographic data were obtained from the survey. Ordinary least square (OLS) models were employed to estimate the impact of clinical conditions on HSU values controlling for sociodemographic conditions. Nonparametric biased-corrected and accelerated (BCA) bootstrap was used to calculate the 95% confidence intervals (CIs). Results. A total of 289 T2D patients provided data. The mean HSU value of the sample was 0.876 (standard deviation: 0.14), with a median of 0.895 (range: −0.063 to 1). Using the OLS model and BCA bootstrap, the impact of significant conditions on HSU values and 95% CIs are as follows: neuropathy (−0.057, [−0.093, −0.017]), heart disease (−0.074, [−0.122, −0.018]), cerebrovascular disease (−0.160, [−0.287, −0.030]), and increasing diabetes duration (−0.004, [−0.007, −0.001]). Conclusion. The HSU values estimated can be used to assess the cost-effectiveness of health care interventions for T2D patients in China.
YangWLuJWengJ.; China National Diabetes and Metabolic Disorders Study Group. Prevalence of diabetes among men and women in China. N Engl J Med. 2010;362:1090–101.
2.
WangWMcGreeveyWPFuC. Type 2 diabetes mellitus in China: a preventable economic burden. Am J Manag Care. 2009;15:593–601.
3.
PriceHCClarkePMGrayAMHolmanRR. Life expectancy in individuals with type 2 diabetes: implications for annuities. Med Decis Making. 2010;30:409–414.
4.
CoffeyJTBrandleMZhouH. Valuing health-related quality of life in diabetes. Diabetes Care. 2002;25:2238–43.
5.
RedekopWKKoopmanschapMAStolkRPRuttenGEWolffenbuttelBHNiessenLW. Health-related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes. Diabetes Care. 2002;25:458–63.
6.
MorganCLMcEwanPMorrisseyMPetersJRPoopleCCurrieCJ. Characterization and comparison of health-related utility in people with diabetes with various single and multiple vascular complications. Diabet Med. 2006;23:1100–5.
7.
DrummondMFSculpherMJTorranceGWO’BrienBStoddartGL. Methods for the Economic Evaluation of Health Care Programmes. 3rd ed.New York: Oxford University Press; 2005
8.
DolanP. Modeling valuations for EuroQol health states. Med Care. 1997;35:1095–108.
9.
FeenyDFurlongWBoyleMTorranceGW. Multi-attribute health status classification systems: health utilities index. Pharmacoeconomics. 1995;7:490–502.
10.
FeenyDFurlongWTorranceGW. Multiattribute and single attribute utility functions for the health utilities index mark 3 system. Med Care. 2002;40:113–28.
11.
GoldMRPatrickDLTorranceGW. Identifying and valuing outcomes. In: GoldMRSiegelJERussellLBWeinsteinMC, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996. p 83–134.
12.
BrazierJRobertsJDeverillM. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002;21:271–92.
13.
JanssenMFLubetkinEISekhoboJPPickardAS. The use of the EQ-5D preference-based health status measure in adults with type 2 diabetes mellitus. Diabet Med. 2011;28:395–413.
14.
JoySMLittleEMaruthurNMPurnellTSBridgesJF. Patient preferences for the treatment of type 2 diabetes: a scoping review. Pharmacoeconomics. 2013;31:877–92.
15.
WexlerDLGrantRWWittenbergE. Correlates of health-related quality of life in type 2 diabetes. Diabetologia. 2006;49:1489–97.
16.
BagustABealeS. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ. 2005;14:217–30.
17.
ClarkePGrayAHolmanR. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making. 2002;22:340–9.
18.
UK Prospective Diabetes Study Group. Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). Diabetes Care. 1999;22:1125–36.
19.
Bourdel-MarchassonIDruetCHelmerC. Correlates of health-related quality in French people with type 2 diabetes. Diabetes Res Clin Pract. 2013;101:226–35.
20.
SakamakiHIkedaSIkegamiN. Measurement of HRQOL using EQ-5D in patients with type 2 diabetes mellitus in Japan. Value Health. 2006;9:47–53.
21.
MaddiganSLFeenyDHJohnsonJA. Health-related quality of life deficits associated with diabetes and comorbidities in a Canadian National Population Health Survey. Qual Life Res. 2005;14:1311–20.
22.
NeumannASchofferONorstromFNorbergMKlugSJLindholmL. Health-related quality of life for pre-diabetic states and type 2 diabetes mellitus: a cross-sectional study in Vasterbotten Sweden. Health Qual Life Outcomes. 2014;12:150.
23.
ShiuATThompsonDRWongRY. Quality of life and its predictors among Hong Kong Chinese patients with diabetes. J Clin Nurs. 2008;17:125–32.
24.
CongJYZhaoYXuQYZhongCDXingQL. Health-related quality of life among Tianjin Chinese patients with type 2 diabetes: a cross-sectional survey. Nurs Health Sci. 2012;14:528–34.
25.
TangWLWangYMDuWMChengNNChenBY. Assessment of quality of life and relevant factors in elderly diabetic patients in the Shanghai community. Pharmacoepidemiol Drug Saf. 2006;15:123–30.
26.
YangJLiSZhengY. Predictors of depression in Chinese community-dwelling people with type 2 diabetes. J Clin Nurs. 2009;18:1295–304.
PanCWSunHPWangX. The EQ-5D-5L index score is more discriminative than the EQ-5D-3L index score in diabetes patients. Qual Life Res. 2015;24:1767–74.
29.
LiuGGWuHLiMGaoCLuoN. Chinese time trade-off values for EQ-5D health states. Value Health. 2014;17:597–604.
30.
van HoutBJanssenMFFengYS. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012;15:708–15.
31.
PullenayegumEMTarrideJEXieFGoereeRGersteinHCO’ReillyD. Analysis of health utility data when some subjects attain the upper bound of 1: are Tobit and CLAD models appropriate?Value Health. 2010;13:487–94.
32.
CarpenterJBithellJ. Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians. Stat Med. 2000;19:1141–64.
33.
DiCiccoTJEfronB. Bootstrap confidence intervals. Stat Sci. 1996;11:189–228.
34.
RobinsJMHernanMABrumbackB. Marginal structure models and causal inference in epidemiology. Epidemiology. 2000;11:550–60.
35.
TsuchiyaAIkedaSIkegamiN. Estimating an EQ-5D population value set: the case in Japan. Health Econ. 2002;11:341–53.
36.
PeetersYStiggelboutAM. Health state valuations of patients and the general public analytically compared: a meta-analytical comparison of patient and population health state utilities. Value Health. 2010;13:306–9.
